Table 4.
Cabazitaxel exposure
| Characteristics | All patients (N=61) | Prior use of abiraterone | p value | |
|---|---|---|---|---|
|
| ||||
| No (n=35) | Yes (n=25) | |||
| Cycles of cabazitaxel, n, median (range) | 6.0 (1–27) | 6 (1–27) | 7 (1–13) | 0.2517 |
| Cumulative dose of cabazitaxel, median (mg/m2) | 259.0 (43–1269) | 268.8 (43–1269) | 259.0 (45–550) | 0.1762 |
| Patients receiving more than 10 cycles of cabazitaxel, n (%) | 15 (24.6) | 10 (28.6) | 5 (20.0) | 0.4535 |
| Relative dose intensity, median* | 100 (80–100) | 100 (82–100) | 100 (80–100) | 0.6991 |
| Dose delay, n (%) | 28 (50.0)** | 16 (45.7) | 12 (57.1) | 0.4118 |
| Dose delays due to: | ||||
| Hematotoxicity | 6 (21.4) | 1 (6.3) | 5 (41.7) | 0.3157 |
| Non-hematotoxicity | 4 (14.3) | 2 (12.5) | 2 (16.7) | |
| Other | 18 (64.3) | 13 (81.2) | 5 (41.7) | |
| Dose reduction, n (%) | 15 (26.8)** | 8 (22.9) | 7 (33.3) | 0.3957 |
| Dose reduction due to: | ||||
| Hematotoxicity | 6 (40.0) | 3 (37.5) | 3 (42.9) | 0.9699 |
| Non-hematotoxicity | 6 (40.0) | 4 (50.0) | 2 (28.6) | |
| Other | 3 (20.0) | 1 (12.5) | 2 (28.6) | |
*
At least 50% of the patients did not have the dose reduction.
**
Only 56 patients were treated with two or more cycles.